Objectives. To evaluate and compare the efficacy and acceptability of the antidepressants amitriptyline (AMT), duloxetine (DLX) and milnacipran (MLN) for FM syndrome (FMS).
Introduction
FM syndrome (FMS) can be diagnosed by a history of a typical cluster of key symptoms (chronic widespread pain, physical fatigue, cognitive disturbances and unrestorative sleep) and the exclusion of a somatic disease that sufficiently explains the symptoms [1, 2] . Recent populationbased studies found a prevalence of FMS of 2.2-6.6% in Western European countries [3, 4] . FMS patients in clinical settings report high levels of disability and cause high direct and indirect health costs [5] . Therefore, effective and safe treatment options for FMS are warranted. Antidepressants such as amitriptyline (AMT), duloxetine (DLX) and milnacipran (MLN) have been recommended by the evidence-based guidelines of the European League against Rheumatism (EULAR) and the Association of Medical Scientific Societies in Germany (AWMF) for pharmacological therapy of FMS [6, 7] .
However, the evidence for pharmacological therapy of FMS with antidepressants is faced with some problems.
First, there is a controversy about the gold standard of pharmacological FMS therapy. AMT was recommended as first-line pharmacological therapy of FMS by an AWMF guideline based on a qualitatitive and quantitative analysis of randomized controlled trials (RCTs) of AMT in FMS, the long-term clinical experience with this drug by most physicians and its availability in Germany [7] . In contrast, another systematic review could not make a definitive clinical recommendation regarding the efficacy of AMT [8] . Secondly, in Europe no drug has been approved specifically for FMS. AMT is approved for the treatment of chronic pain syndromes in some European countries such as Austria, Germany, Belgium and Norway (personal communication: GmbH, Hamburg, Germany). DLX and MLN were rejected by the European Medical Agency (EMEA) for the treatment of FMS because the effects of DLX and MLN were considered to be too small to be relevant for patients [9, 10] . In contrast, both drugs have been approved by the US Food and Drug Administration for FMS [11] . Thirdly, there is uncertainty about the acceptability of antidepressant therapy of FMS to patients. The assumption that new drugs, such as DLX and MLN, are better tolerated than old drugs, such as AMT [12] , has to our knowledge not been tested by direct head-to-head comparisons between these drugs.
Recently, comparative effectiveness research has been promoted in the USA to assess whether new (and more expensive) drugs provide an additional benefit compared with standard therapies [13] . In the case of head-to-head comparisons, formal adjusted indirect methods summarize combined estimates and incorporate additive variance from both sets of trials. Recently, we compared the efficacy and safety of DLX, MLN and PGB in FMS [14] . Meanwhile, two other large RCTs with MLN in FMS had been published [15, 16] , which had not been included in the analysis. Therefore, we saw the need to update the formal adjusted indirect comparisons of DLX and MLN and to compare their efficacy in reducing FMS symptoms and their acceptability with those of AMT.
Methods
The review was performed according to the PRISMA (preferred reporting items for systematic reviews and meta-analyses) statement [17] . Meta-analysis was performed following the recommendations of the Cochrane Collaboration [18] .
Protocol
Methods of analysis and inclusion criteria were specified in advance. We used the review protocol of our systematic review on DLX, MLN and pregabalin in FMS [14] .
Eligibility criteria

Types of studies and interventions
RCTs comparing AMT, DLX or MLN with pharmacological placebo were included. RCTs in which drugs were combined with any other defined treatment were excluded.
Types of participants
Patients diagnosed with FMS according to recognized criteria, of any age, were included.
Type of outcome measures
Studies should assess at least one key domain of FMS [pain, sleep, fatigue or health-related quality of life (HRQOL)] [19] and report treatment discontinuation rates (number of patients who terminated the study early for any reason during the study). Discontinuation rates are considered to be the most consistently reported estimate of treatment acceptability [20] .
Data synthesis and analysis Non-parametric tests were used for the comparison of continuous variables and chi-squared tests for the comparison of categorical variables. Data are presented as median (range). A two-sided P 4 0.05 was considered statistically significant.
Meta-analyses were conducted using RevMan Analyses software (RevMan 5.0.24) of the Cochrane Collaboration [24] and comprehensive meta-analysis software [25] . Standardized mean differences (SMDs) were calculated by means and S.D.s for each interventions. Examination of the combined results was performed by a random-effects model (inverse variance method), because this model is more conservative than the fixed-effects model and incorporates both within-and between-study variance [26] . SMD used in Cochrane reviews is the effect size known as Hedges' (adjusted) g. We used Cohen's categories to evaluate the magnitude of the effect size, calculated by SMD, with g > 0.2-0.5 = small effect size, g > 0.5-0.8 = medium effect size and g > 0.8 = large effect size [27] .
Numbers needed to treat (NNT) were calculated using the pooled number of observations. If the number of patients with a 30% pain reduction was not reported, it was calculated by the means and S.D.s of pain scores at baseline and post-treatment by an imputation method with worst case analysis (number of patients imputed at baseline) [28] .
We performed adjusted indirect comparisons using the method described by Bucher et al. [29] . We calculated indirect relative risks (RR ind ) for AMT vs DLX, AMT vs MLN and DLX vs MLN, adjusted by the results of their comparisons against placebo: RR ind = RR Drug [30] .
Planned methods of analysis
Heterogeneity was tested using the I 2 statistic with I 2 > 50% indicating strong heterogeneity [18] . The similarity assumption for adjusted indirect comparisons [31] was tested by comparing the clinical (exclusion criteria, patients' ages, percentage of women and Caucasians, treatment duration) characteristics and methodological quality of the studies.
Additional analyses
Subgroup and sensitivity analysis
Subgroup analyses were prespecified for the continent in which the study was conducted, because the EMEA doubted the long-term efficacy of MLN in European patients [10] and for AMT studies with parallel vs crossover design because Nishishinya et al. [8] reported that none of the cross-over trials provided separate baseline data before the cross-over therapy [8] . Post hoc we decided to perform a subgroup analysis of AMT studies with and without support from pharmaceutical companies. These subgroup analyses were also used to examine potential sources of clinical heterogeneity.
We decided post hoc to perform a sensitivity analysis of AMT studies with and without extracting values from figures and of studies with and without intention-to-treat analysis.
Meta-regression analysis
A priori we planned to meta-regress the effect size on pain with the methodological quality score. Meta-regression was performed using the mixed effects model. The t 2 variance was calculated by the method of unrestricted maximum likelihood by Comprehensive Meta-analysis software [25] .
Risk of bias across studies
Potential publication bias (i.e. the association of publication probability with the statistical significance of study results) was investigated using visual assessment of the funnel plot (plots of effect estimates against its S.E.) calculated by RevMan Analyses software, if appropriate (at least 10 studies available). Publication bias may lead to asymmetrical funnel plots [18] .
Additionally, we performed the Egger test, in which the standardized effect size (effect size calculated by S.E.) is regressed on precision (inverse of S.E.). The intercept value is an estimate of asymmetry of funnel plot.
Positive values (>0) indicate higher levels of effect size in studies with smaller sample sizes [32] .
Results
Search results
The search yielded 246 hits. We found no studies with head-to-head comparisons of the three drugs. After article review, five studies with AMT and one study each with DLX and MLN were excluded. In two studies, AMT was combined with another defined treatment (guided imagery, cardiovascular training) [33, 34] . One AMT study used a N-of-1 design [35] , one was a double publication [36] , one had no pharmacological placebo [37] , one study had no placebo group [37] and one was only published as an abstract [38] . The data of one study each with DLX and MLN had not been published [39, 40] . Ten RCTs with AMT [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] , four with DLX [51] [52] [53] [54] and five with MLN [12, 15, 16, 55, 56] were included in qualitative and quantitative analysis (supplementary figure 1, available as supplementary data at Rheumatology Online).
Study characteristics
Data are reported as median (range): five of the AMT trails were (co-)sponsored by pharmaceutical companies. All DLX and MLN trials were sponsored by the manufacturer of the drug. Six of the AMT studies were conducted in North America, one in South America and three in Europe. Two of the DLX studies were conducted in North America and one each in North America/Middle America and North America/Europe. Four MLN studies were conducted in North America and one in Europe. The AMT trials recruited patients from the institutions involved. The MLN trials recruited patients from the institutions involved and by referral, the DLX studies recruited additional patients by advertisement. All trials excluded patients with severe somatic diseases. Patients with severe mental disorders were excluded in three AMT trials and in all MLN trials. The DLX studies excluded patients with severe mental disorders except for major depression. All studies used a parallel design except three AMT studies with a cross-over design. A total of 612 patients were randomized in the AMT trials, 1411 in the DLX trials and 4129 in the MLN trials. The study duration in AMT trials was 8 (4-26), in DLX trials 19 (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) and in MLN trials 16 (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) weeks (H = 9.2, P = 0.01). The average age in AMT trials was 44.4 (38-53) , in DLX trials 51 (50) (51) Only acetaminophen was allowed in the AMT studies for rescue medication. Acetaminophen and ASA were allowed in the DLX studies, one of the studies allowed NSAIDs and narcotics additionally. Hydrocodone was used in the MLN studies for rescue medication and these studies additionally allowed stable doses of ASA, acetaminophen and NSAIDs (Table 1) .
Outcome measures
There was great variability between the studies in the outcome measures used and in the domains assessed. The AMT and DLX studies used questionnaires with visual or numerical pain ratings and four MLN studies used electronic diaries. HRQOL was assessed only by three AMT studies. Sleep quality was measured only in one DLX study. The same outcome measures were used in the four large MLN trials ( Table 1 ). The imputing method for ITT analysis for the outcomes meta-analysed in DLX and MLN trials was the last observation carried forward method. The two AMT studies with ITT did not report on the imputing method.
Methodological quality
The reported methodological quality of seven AMT trials was poor and two were moderate. Only two studies analysed the data per ITT. We did not succeed in getting to know the details missing in the publications from the authors. The reported methodological quality of three DLX trials and two MLN trials was low; of one DLX trial and two MLN trials moderate; and of one MLN trial high. The methodological quality of all DLX and MLN studies was high for all studies after the provision of details of the methodology and some outcome data on request ( (Table 3) .
Comparative efficacy
In adjusted indirect analyses, AMT was superior to DLX and MLN in reduction of pain, sleep disturbances, fatigue and limitations of HRQOL. DLX was superior to MLN in reducing pain, sleep disturbances and limitations of HRQOL. MLN was superior to DLX in reducing fatigue. AMT was superior to DLX and MLN in 30% pain reduction. There were no significant differences in the acceptability (drop-out rates) between the three drugs (Table 4) .
Subgroup and sensitivity analyses
There were no significant effects on pain for AMT and DLX studies conducted in Europe and in AMT studies with industrial support and parallel design ( Table 5 
Meta-regression
Post hoc we decided to meta-regress outcomes with methodological quality only for AMT trials because the methodological quality of the DLX and MLN trials was, after requests, equivalent. There was no significant correlation of the cumulative Cochrane risk of bias tool and the SMD of AMT on pain ( = 0.06, P = 0.6).
Publication bias
Visual inspection of the funnel plots of the AMT studies was not suggestive of a publication bias. The Egger's intercept was positive (3.36), but not significant (two-tailed P = 0.10). Data not included in publication; not provided on request. 
Discussion
Summary of evidence
In adjusted indirect comparisons, AMT was superior to DLX and MLN in reducing FMS symptoms. The evidence of superior efficacy of AMT over DLX and MLN is weakened by the methodological problems of some AMT trials. A significant effect on pain was only found in studies with cross-over design, no ITT analysis and non-European patients. However, within a conservative approach of imputing reponse rates for 30% pain reduction of AMT trials, the superior efficacy of AMT over DLX and MLN in pain reduction was confirmed. There were no significant differences between the three drugs in terms of acceptability.
Agreement with other systematic reviews
Our results are in line with a recent systematic qualitative review on AMT in FMS, which concluded that AMT demonstrated a therapeutic response compared with placebo in the domains of pain, sleep and fatigue [8] . In contrast to Nishishinya et al. [8] , we performed a quantitative synthesis of the AMT trials because the heterogeneity of most outcomes of AMT was not as high as suggested by the authors. We addressed the methodological pitfalls of some AMT trials, which had been worked out by the authors by subgroup and sensitivity analyses and meta-regression. Adding two large RCTs with MLN in indirect comparison with DLX did not change the results of our previous indirect comparison of the two drugs [14] . Pretends that only data of ITT were reported, but Table 4 includes complete analysis. Adequacy of randomization: a random (unpredictable) assignment sequence. Examples of adequate methods are computer-generated random number table and use of sealed opaque envelopes. Methods of allocation using date of birth, date of admission, hospital numbers or alternation were regarded as appropriate. Adequacy of concealment of treatment allocation: assignment generated by an independent person not responsible for determining the eligibility of the patients. This person has no information about the persons included in the trial and has no influence on the assignment sequence or on the decision about eligibility of the patient (e.g. hospital pharmacy, central independent unit). Adequacy of blinding: patient and care provider and outcome assessor were blinded to the intervention. Complete reporting of outcomes: all outcomes assessed in the study were reported. Intention-to-treat analysis: all randomized patients are reported/analysed in the group they were allocated to by randomization (minus missing values). Agreement with excluded studies
Three of four excluded studies confirmed the efficacy of AMT in reducing some FMS symptoms. In 7 of 23 N-of-1 trials, AMT 10-50 mg/day over 3-12 weeks was superior to placebo in reducing a symptom score of pain, fatigue, sleep, morning stiffness, headache and bowel problems [35] . In an 8-week trial, AMT 10 mg was superior to laser placebo in reducing morning stiffness [37] . In a 12-week trial, AMT 25 mg was superior to placebo in reducing fatigue, but not pain or sleep disturbance [38] . In a The total number of patients in the comparisons is higher than the total number of patients in the studies because different dosages of DLX and MLN were compared with the same placebo group in some trials with DLX and MLN.
4-week study, AMT 10-50 mg/day combined with guided imagery was not superior to guided imagery combined with pharmacological placebo in reducing pain [33] .
Limitations
The major methodological limitation of the analysis is that the similarity assumption for indirect comparisons was only partially fulfilled. Some patient characteristics differed significantly, but in our opinion that was not clinically relevant between AMT studies and DLX/MLN trials. The methodological quality of the AMT studies was lower than that of the DLX and MLN studies. Therefore, the results of the adjusted indirect comparisons should be interpreted with caution. We did not succeed in receiving missing outcome data of one AMT trial and the methodological details of all AMT trials. The missing outcomes of pain, sleep and fatigue in the study of Heymann et al. [36] would probably not change the results of our quantitative analysis because AMT had a strong effect on the FM impact questionnaire (FIQ) total score in this study. The FIQ total score comprises the missing outcomes.
Conclusions
Clinical practice
The recommendation of the German FMS guideline that AMT is the first pharmacological treatment option is substantiated by the indirect comparison of AMT with DLX and MLN, and the lack of approval of DLX and MLN for FMS in Europe. In contrast to DLX and MLN, AMT has moderate effects on sleep and small effects on fatigue, thus covering three key symptoms of FMS. However, the dosages of AMT in the FMS trials (10-50 mg/day) did not reduce depressed mood [22] . DLX is approved in most European countries for major depression. Its efficacy in pain reduction had been shown for FMS patients with and without major depression. Therefore, DLX can be regarded to be the first option for FMS patients with major depression. The different profiles of side effects of the three drugs [8, 14] and their relevance for the individual might also influence the choice of drug. It should be noted that a postive effect on FMS symptoms of AMT has only been confirmed for 3 months and of DLX and MLN for up to 6 months in placebo-controlled trials. Therefore, trial of omission can be discussed with responders after these time intervals.
Research
More stringent RCTs with longer follow-up periods are required to determine the long-term efficacy and safety of AMT [8] . We recommend that the EMEA requires for future approval of new drugs that they provide an additional benefit compared with standard therapies such as AMT. Meanwhile, head-to-head comparisons of the three drugs should be conducted with patient samples representative of clinical practice. These samples should include patients with comorbid anxiety and affective disorders, which are frequently associated with FMS [57] . These studies should be conducted in America as well as in Europe and Asia. Without financial support the required multinational studies will not be possible. Funding by public sources instead of pharmaceutical companies might be preferable.
Rheumatology key messages
. Adjusted indirect comparisons of the efficacy of AMT, DLX and MLN in FM were calculated. . AMT was superior to DLX and MLN in reducing pain, sleep disturbances and fatigue. . The validity of the indirect comparison was limited by the low methological quality of AMT trials. 
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